Kala Pharmaceuticals (KALA) Stock Analysis: AI Score & Alternative Data
KALA alt-data: sentiment climbing, web traffic lagging
Is Kala Pharmaceuticals a buy right now? The alternative data says hold. This KALA stock analysis is built on the 25+ alternative data signals AltIndex tracks on Kala Pharmaceuticals every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 44/100: a Hold. The stock trades at $0.92 with a $16M market cap.
The bullish side of the 90-day ledger: sentiment up 17.6% to 100/100. The drag: web traffic down 29.6% to 6K monthly visits, and just 47% of employees report a positive business outlook. That tension is what keeps the score mid-range.
KALA’s broader alt-data profile also covers headcount (81 employees, according to LinkedIn), and Reddit mentions (1 a day). Every signal links to its own page with full history, the KALA technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on KALA is just below.
Kala Pharmaceuticals AI Stock Analysis
Kala Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of eye disease therapies. The company's main products and research initiatives target various ocular conditions, leveraging its proprietary technologies to advance treatment options for patients.
Analysis generated August 1, 2026.
Recent Kala Pharmaceuticals Stock Alerts
|
Kala Pharmaceuticals | August 13 Price is up by 9.8% in the last 24h. |
|
Kala Pharmaceuticals | August 12 Price is up by 8.2% in the last 24h. |
|
Kala Pharmaceuticals | August 11 Price is up by 7.3% in the last 24h. |
|
Kala Pharmaceuticals | August 10 Price is up by 7.5% in the last 24h. |
Kala Pharmaceuticals Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 6K | 29.6% | |
| LinkedIn Employees | 81 | 1.3% | |
| Employee Recommend | 64 | 0% | |
| Business Outlook | 47 | 0% | |
| Sentiment | 100 | 17.6% | |
| Reddit Mentions | 1 | 0% | |
| X Mentions | 5 | 79.2% | |
| Stocktwits Mentions | 5 | 92.2% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 10K | 1.8% | |
| 4chan Mentions | 0 | N/A |
About Kala Pharmaceuticals (KALA)
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.
| Price | $0.92 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $16M |
| Year Range | $1 – $982 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Kala Pharmaceuticals News
View more →
Ophthalmic Clinical Trials Market Size to Reach USD 3.30 Billion by 2035 as Gene Therapy and Retinal Disease Drug Development Accelerate – SNS InsiderJune 18 - GlobeNewswire |
|
 |
Which stocks have an unusual volume on Friday?March 13 - ChartMill |
|
Which stocks have an unusual volume on Thursday?March 12 - ChartMill |
 |
12 Health Care Stocks Moving In Thursday's Intraday SessionMarch 11 - Benzinga |
 |
Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionMarch 11 - Benzinga |
Kala Pharmaceuticals Earnings & Financial Performance
View all earnings →Kala Pharmaceuticals Insider Trading Activity
View all →| Reumuth Mary filed to sell 28,906 shares at $0.0. Oct 23 '25 |
| Iwicki Mark T filed to sell 103,540 shares at $0.0. Oct 23 '25 |
| Brazzell Romulus K filed to sell 35,952 shares at $0.0. Oct 22 '25 |
| Bazemore Todd filed to sell 35,932 shares at $0.0. Oct 22 '25 |
| Reumuth Mary filed to sell 29,873 shares at $0.0. Oct 22 '25 |
Kala Pharmaceuticals Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Kala Pharmaceuticals
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Pasithea TherapeuticsKTTA |
$0.48 2.5% | $16M | 46 |
 |
LipocineLPCN |
$2.06 0.0% | $17M | 57 |
 |
Vyome HoldingsHIND |
$2.16 2.7% | $16M | 48 |
 |
Cocrystal PharmaCOCP |
$1.10 1.8% | $15M | 50 |
 |
Sensei BiotherapeuticsSNSE |
$13.85 6.5% | $17M | 64 |
Explore Kala Pharmaceuticals Data
Frequently Asked Questions: Kala Pharmaceuticals (KALA)
Kala Pharmaceuticals has an AltIndex AI Score of 44/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
44/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Kala Pharmaceuticals (KALA) stock is $0.92 with a market cap of $16M.
As of today, Kala Pharmaceuticals’s PE (Price to Earnings) ratio is —.
View the latest Kala Pharmaceuticals insider transactions to see recent buying and selling activity by company executives and directors.
Check the Kala Pharmaceuticals congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The KALA stock price chart above shows Kala Pharmaceuticals’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Kala Pharmaceuticals technical analysis for RSI, moving averages, and more.
See the stocks similar to Kala Pharmaceuticals section on this page for companies in the same industry ranked by market cap and AI Score.
